Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
about
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individualsConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralizationHuman rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysVaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoproteinInduction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionA critical question for HIV vaccine development: which antibodies to induce?Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibodyEnhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.Simple enzyme immunoassay for titration of antibodies to the CD4-binding site of human immunodeficiency virus type 1 gp120.Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccinesAutologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humansCharacterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboonsNeutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibodyVariant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophagesA predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120.Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.Immunization of chimpanzees confers protection against challenge with human immunodeficiency virusPrediction of optimal peptide mixtures to induce broadly neutralizing antibodies to human immunodeficiency virus type 1.Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response.The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domainExamination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.
P2860
Q24560010-AE276933-E9E3-4C22-9741-449B05746E55Q26782237-E73C0044-6898-4EC1-806F-7C47505180CAQ27469855-8692C5F4-BAB5-4DFA-A77B-E1E99C7FD1A9Q28646835-8C2DE512-0B1D-4501-9E42-9EBCD0EC9759Q29615898-700D11EC-F188-4824-AC27-48F8D997457FQ32157115-83B9CD32-57FF-4A6E-B550-3E292D2ECDCDQ33210858-29292916-B3D5-46E4-8A85-EC1CD0FF904BQ33785114-3589F36B-8A55-4789-9CA6-9B3E2DA53A64Q33786386-F8D01D87-5EA3-4F43-A579-BEAEF34287A9Q33821658-D5FB2645-397B-4913-B596-4D138FC02FCAQ33933098-9E0DC02F-43CC-42F8-8BB3-395F77C812BDQ33937274-E3406B03-9C7F-4326-BEAD-A1C974E88309Q34069214-34306F16-EC6E-475F-B1D5-6EC2F0FBC2ABQ34097650-D1986DB0-8FC5-4037-8CCA-F46734794E5AQ35224610-26E9284E-0E18-4EBC-861F-BE74E23A488AQ35783015-D5B8A6FF-BBB1-4CEE-AE68-F8827736F0F8Q35866030-15C49E58-EB32-4784-8586-453BCB26B3CAQ36230737-F1FFDED7-67AB-43AC-959A-4C7A2E6F7163Q36526779-5216097F-C5DB-42C3-9B29-2D45D648269CQ36623941-CB15307F-D697-48D6-A517-1359161288EEQ36630114-6C62FD7D-421B-49E5-8646-BEF817A72B85Q36644253-4BDDD4F7-4B4F-4D8A-BEEB-F31D4718571CQ36649958-790AA2C9-8B2D-4DB2-8D48-855B6A1DA440Q36651761-B4E99DE0-15CC-4C01-976F-546772F00790Q36655953-9558A4DE-CB5C-45FD-A0C0-3A1C03DE94C2Q36687562-2019829A-6F5C-478E-BDAB-42F5601E7C93Q36694332-6ED1546A-4192-4203-9F58-6B37CF8CE987Q36697629-50CEA16C-492C-4531-A51A-EC1F59EB2B65Q36797335-93588C7E-0790-4009-841E-4D719D54E53CQ36821056-586B4669-3C39-4906-94DC-C415092D1DB5Q36821885-49778C99-7B03-4521-9260-9AC9FB88A2D9Q36839199-E72B8E9C-7ABA-4749-BE1D-9593D5117FA3Q37239053-67952EFC-C14F-461C-ABCF-EBA5FAE21991Q37375345-7F2DF2CF-FC29-4C6C-8461-4E6E218907DFQ37567048-E8B44C1D-FBFD-4A8A-901B-8ED9B0D063AFQ37587941-684A1DB3-9165-4153-B661-020C330BFF1EQ39439112-7B31C8F4-9395-4E8F-B775-0EFF6E29DE27Q39579497-75D6F04D-A59F-488A-B3D2-7835E45C7393Q40015450-8DBE58BC-E8A5-44FE-8CE4-F7721137E999Q40038277-44AD788F-E969-4BDF-822A-02C52C63F2CB
P2860
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Antibody-mediated in vitro neu ...... es infectivity for chimpanzees
@ast
Antibody-mediated in vitro neu ...... es infectivity for chimpanzees
@en
type
label
Antibody-mediated in vitro neu ...... es infectivity for chimpanzees
@ast
Antibody-mediated in vitro neu ...... es infectivity for chimpanzees
@en
prefLabel
Antibody-mediated in vitro neu ...... es infectivity for chimpanzees
@ast
Antibody-mediated in vitro neu ...... es infectivity for chimpanzees
@en
P2093
P2860
P1433
P1476
Antibody-mediated in vitro neu ...... es infectivity for chimpanzees
@en
P2093
J P Davide
S D Putney
S Matsushita
W A Schleif
P2860
P304
P407
P577
1990-08-01T00:00:00Z